Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
March 1, 2021
RegMed Investors’ (RMi) closing bell: sector rebounds after a tough February
March 1, 2021
RegMed Investors’ (RMi) pre-open: a new month, rotating with a sentiment boost
February 26, 2021
RegMed Investors’ (RMi) closing bell: telling a sector story with daily data
February 19, 2021
RegMed Investors’ (RMi) closing bell: Zip-a-dee-doo-dah, zip-a-dee-ay; my, oh, my, what a wonderful session
February 19, 2021
RegMed Investors’ (RMi) pre-open: follow the potential of bouncing share pricing and a few more falling knives or not
February 18, 2021
RegMed Investors’ (RMi) closing bell: a session of falling knives
February 18, 2021
RegMed Investors’ (RMi) pre-open: bottom, bottom where and which is the dip worth buying
February 17, 2021
RegMed Investors’ (RMi) closing bell: share pricing pressures
February 17, 2021
RegMed Investors’ (RMi) pre-open: prudence can be an action, a virtue or a burden
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors